Exor H1 2025: Strategy still in waiting
26/09/25 -"Exor posts a modest NAV uptick, yet the lift owes more to share buybacks than portfolio strength. Liquidity is at record levels, but the path ahead is ambiguous. Luxury, tech, and healthcare are ..."
Pages
56
Language
English
Published on
26/09/25
You may also be interested by these reports :
13/01/26
We have materially lowered our target price while maintaining a constructive long-term outlook. This downward revision mainly reflects the recent ...
07/01/26
Q1 revenue was aligned with consensus, with uneven geographic performance: Continental Europe faced macro headwinds and delivered modest growth, ...
06/01/26
Benefitting from elevated inflation and interest rates, which support higher issuance volumes and float income, Edenred (BUY ; France) reached an ...
05/01/26
With no near-term visibility on Edenred’s joint appeals against the recent regulatory changes in Italy and Brazil, we have finally revised our ...